The move expands access to specialist-led skin cancer detection services across Australia.
Skin cancer detection and surveillance company MoleMap has acquired workplace and regional skin screening provider Spotscreen, expanding its reach across Australia.
The deal brings Spotscreen’s mobile screening operations into the MoleMap network, combining workplace-based skin checks with MoleMap’s specialist-led surveillance model that integrates trained melanographers, dermatologist assessment and advanced imaging technology.
MoleMap Australia New Zealand chief executive Michelle Aquilina said the acquisition would strengthen access to early detection services across metropolitan, regional and workplace settings.
“Australia and New Zealand have the highest melanoma rates in the world, and MoleMap is building the most advanced skin cancer surveillance network to detect melanoma and skin cancer earlier, at scale,” she said.
“We are committed to pioneering early detection and improving outcomes across the ANZ region.
“The acquisition of Spotscreen increases our ability to deliver our services to more of the population, both direct to consumer and through workplaces.”
Spotscreen, established in 2011, has focused on delivering mobile skin cancer screening and sun safety education programs to workplaces including mining, corporate and government organisations.
Related
The company’s corporate director Andrew Sheppard said the integration would broaden access to specialist support and technology-driven surveillance pathways.
“As a family-run business with a deep, personal connection to skin cancer, we have made it our mission to improve early detection rates and educate Australians on prevention,” Mr Sheppard said.
“MoleMap’s clinical governance, technology and specialist network will allow Spotscreen to deliver even stronger outcomes for the people and organisations we serve.”
Spotscreen clients will continue to receive workplace screening services under the new arrangement, while gaining access to MoleMap’s imaging and longitudinal monitoring systems.
The acquisition comes as health services continue to emphasise the role of early detection in reducing melanoma morbidity and mortality, particularly in high-risk populations and geographically underserved communities.
